MRPI Mera Pharmaceuticals Inc. featured news, full reports, and detailed charts
Mera Pharmaceuticals Inc. (MRPI/MRPI.PK) Wrap Up:
Mera Pharmaceuticals, Inc. engages in the development and commercialization of natural products from microalgae using its Mera Growth Module photobioreactor technology. The company’s principal product line includes AstaFactor, a nutraceutical that is derived from Haematococcus microalgae. The AstaFactor product line consists of AstaFactor Rejuvenating Formula, AstaFactor Sports Formula, and AstaFactor Salmon Essentials. These products target specific health benefits primarily focusing on immune system, cardiovascular, neurological disorders, and anticancer. The company sells its products to mass retail outlets in Hawaii. Mera Pharmaceuticals was incorporated in 1987 and is based in Kailua-Ko...www.merapharma.com
6 Employees
Founded in 1987
Mera Pharmaceuticals Inc. (MRPI:OTC)
|
Market Cap
2.5M
|
Total Revenue
655.6K
|
|
|
EBITDA
137.3K
|
DILUTED EPS TTM
0.00
|
|
|
P/E
--
|
P/S
3.8x
|
|
|
Return On Asset
-10.80
|
Return On Equity
-232.90
|
|
| K = Thousands M = Millions B = Billions | ||
MRPI Top Compensated Officers
Mr. Gregory F. Kowal
Chairman and Chief Executive Officer
Age: 60
Total Annual Compensation: --
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Mera Pharmaceuticals Inc. (MRPI)
Mera Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
01/16/2009
Mera Pharmaceuticals Inc. filed its 10KSB on January 16, 2009 for the period ending October 31, 2008. In this report its auditor, Jewett, Schwartz, Wolfe & Associates, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Mera Pharmaceuticals Seeks To Raise Funds
01/16/2009
Mera Pharmaceuticals Inc. informed that as of October 31, 2008 it had 547,759,915 shares of common stock outstanding. The company stated, “We may need additional funding for capital expenditures and operating capital. If we raise additional funds by selling equity securities, the share ownership of our existing investors could be diluted. In addition, new equity purchasers may obtain rights, preferences or privileges that are superior to those of our existing stockholders.”
Mera Pharmaceuticals Inc. Announces Board Changes
07/25/2008
On July 23, 2008, Daniel P BeHarry resigned from the Board of Directors and Officer of Mera Pharmaceuticals Inc. to pursue other interests. On July 24, 2008, Michael F. Corcoran, PH.D and Russell M Yamamoto were appointed as members of the Board of Directors of the Company. Dr. Corcoran founded Gull Rock Services in 1989 and National Data Solutions, LLC, in 2002. Mr.Yamamoto is the President and CEO of RMY Construction, Inc. which he founded in 1984.
MRPI Competitors
| Company | Last | Change |
| BASF | €39.87 EUR | -0.02 |
| Cell Tech International Inc | $0.03 USD | 0.00 |
| Martek Biosciences Corp | $18.11 USD | +0.74 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MRPI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.7x |
|
|
MRPI |
||
|
MRPI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Mera Pharmaceuticals Inc.
More news for MRPI
MERA PHARMACEUTICALS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
MERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Report contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements that include the words "believes," "expects," "estimates," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Risk factors include, but are not limited to, our ability to raise or generate additional capital; our ability to cost-effectively manufacture our products on a commercial scale; the concentration of our current customer base; competition; our ability to comply with applicable regulatory requirements; potential need for expansion of our production facility; the potential loss of a strategic relationship; inability to attract and retain key personnel; management's ability to effectively manage our growth; difficulties and resource constraints in developing new products; protection and enforcement of our intellectual property; compliance with environmental laws; climate uncertainty; currency fluctuations; exposure to product liability lawsuits; and control of our management and affairs by principal stockholders. The reader should carefully consider, together with the other matters referred to herein, the information contained under the caption "Risk Factors" in our Annual Report on Form 10-KSB for a more detailed description of these significant risks and uncertainties. We caution the reader, however, that these factors may not be exhaustive. Since inception, our primary operating activities have consisted of basic research and dev...Click here to read the whole Article (external link)
MERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Report contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements that include the words "believes," "expects," "estimates," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Risk factors include, but are not limited to, our ability to raise or generate additional capital; our ability to cost-effectively manufacture our products on a commercial scale; the concentration of our current customer base; competition; our ability to comply with applicable regulatory requirements; potential need for expansion of our production facility; the potential loss of a strategic relationship; inability to attract and retain key personnel; management's ability to effectively manage our growth; difficulties and resource constraints in developing new products; protection and enforcement of our intellectual property; compliance with environmental laws; climate uncertainty; currency fluctuations; exposure to product liability lawsuits; and control of our management and affairs by principal stockholders. The reader should carefully consider, together with the other matters referred to herein, the information contained under the caption "Risk Factors" in our Annual Report on Form 10-KSB for a more detailed description of these significant risks and uncertainties. We caution the reader, however, that these factors may not be exhaustive. Since inception, our primary operating activities have consisted of basic research and dev...Click here to read the whole Article (external link)
MERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Report contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements that include the words "believes," "expects," "estimates," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Risk factors include, but are not limited to, our ability to raise or generate additional capital; our ability to cost-effectively manufacture our products on a commercial scale; the concentration of our current customer base; competition; our ability to comply with applicable regulatory requirements; potential need for expansion of our production facility; the potential loss of a strategic relationship; inability to attract and retain key personnel; management's ability to effectively manage our growth; difficulties and resource constraints in developing new products; protection and enforcement of our intellectual property; compliance with environmental laws; climate uncertainty; currency fluctuations; exposure to product liability lawsuits; and control of our management and affairs by principal stockholders. The reader should carefully consider, together with the other matters referred to herein, the information contained under the caption "Risk Factors" in our Annual Report on Form 10-KSB for a more detailed description of these significant risks and uncertainties. We caution the reader, however, that these factors may not be exhaustive. Since inception, our primary operating activities have consisted of basic research and dev...Click here to read the whole Article (external link)
MERA PHARMACEUTICALS INC Files SEC form 10KSB/A, Annual Report
Show all filings for MERA PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 10KSB/A for MERA PHARMACEUTICALS INC 23-Jan-2009Annual Report Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intende...Click here to read the whole Article (external link)
MERA PHARMACEUTICALS INC Files SEC form 10KSB, Annual Report
Show all filings for MERA PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 10KSB for MERA PHARMACEUTICALS INC 16-Jan-2009Annual Report Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended ...Click here to read the whole Article (external link)
Would you like to leave a comment about Mera Pharmaceuticals Inc. MRPI/MRPI.PK
Find out what social network information about Mera Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Mera Pharmaceuticals Inc. there is more great information available at Realpennies.com